Molnupiravir: From Hope to Epic Fail?
Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far. However, it has recently been associated with very poor clinical efficacy, the risk of creating novel SARS-CoV-2 varia...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2022-11-01
|
| Schriftenreihe: | Viruses |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/1999-4915/14/11/2560 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|